Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load [clinicaltrials:NCT00454337]

Bio2RDF identifier

NCT00454337

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00454337

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00454337

acronym [clinicaltrials_vocabulary:acronym]

EASIER

http://www.w3.org/2001/XMLSchema#string

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

170

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00454337 arm group 9dac59d7871e96c12b1d524b61530085 [clinicaltrials_resource:NCT00454337/arm-group/9dac59d7871e96c12b1d524b61530085]

NCT00454337 arm group eb2abfe346ea2485eec47fffcaecac4c [clinicaltrials_resource:NCT00454337/arm-group/eb2abfe346ea2485eec47fffcaecac4c]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:f75c5a855582d3b6ab2bcdae185de445

brief summary [clinicaltrials_vocabulary:brief-summary]

Switching from enfuvirt ...... de-based combination therapy)

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Tolerance of the ...... s With Undetectable Viral Load

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:37b7f7460cdbdccad7638468139d1431]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:06a9610e90b1efe2dda3dcf10868c4f5]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:0cd17ee4b01e74ef419c57aad15ed375]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:23e3846c4b4878b0010dd726e72ca2f1]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:369566431a7b9a624ddff9cb580cfc7f]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:556bfb38f5eb2e916dff0fef55424301]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:62c9e59fa1f99bd9336fa4a05fd3bc64]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:833527bd373513eb40106abca324dbeb]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:d2a2d7bee496a7a375e21144623d310d]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:d541d0b9dcdf292fcf9f7b8d1e668f5e]

comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm W24 [clinicaltrials_resource:d5cf4827dfec73759c7c1fa2c2f6f4f8]

collaborator [clinicaltrials_vocabulary:collaborator]

French National Agency for Research on AIDS and Viral Hepatitis [clinicaltrials_resource:70aef9de6f48dc8b934933b4434a772f]

completion date [clinicaltrials_vocabulary:completion-date]

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

HIV Infections [clinicaltrials_resource:3f980d9baec1b9b18d5a0f38f4921607]

country [clinicaltrials_vocabulary:country]

France [clinicaltrials_resource:0309a6c666a7a803fdb9db95de71cf01]

detailed description [clinicaltrials_vocabulary:detailed-description]

In patients who have fa ...... instead of enfuvirtide.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00454337 [clinicaltrials_resource:b0b7b7203a437aa12489ad92d2374498]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

FTC/TDF + EFV or LPV/R [clinicaltrials_resource:492f5e33399f942c4d8a54cec80cd754]

FTC/TDF + EFV or LPV/R +T20 [clinicaltrials_resource:bc34445cad84f6b897de95ca6fa22b0b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Enfuvirtide [clinicaltrials_resource:3718e50a8e65965fe703db6de19f714e]

Lopinavir [clinicaltrials_resource:6436a035d235ba79a2f88d2b45e2136f]

Emtricitabine [clinicaltrials_resource:bcab48e50e5e357c9b174a9b5fd8cbad]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

HIV-1 infection

http://www.w3.org/2001/XMLSchema#string

enfuvirtide

http://www.w3.org/2001/XMLSchema#string

raltegravir

http://www.w3.org/2001/XMLSchema#string

treatment experienced

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

French National Agency for Research on AIDS and Viral Hepatitis [clinicaltrials_resource:70aef9de6f48dc8b934933b4434a772f]

location [clinicaltrials_vocabulary:location]

Service des maladies infectieuses et tropicales Hopital Saint Louis [clinicaltrials_resource:47ca2262072f3673916dd252bcd8fe2f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00454337

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Randomized Non-inferiority Stu ...... Copies Per ml.ANRS 138 EASIER

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2007-000162-20

http://www.w3.org/2001/XMLSchema#string

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

ANRS 138 EASIER

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) [clinicaltrials_resource:fb3c6a58c19342bc2492e3a9c9e99df9]

start date [clinicaltrials_vocabulary:start-date]

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00454337 study design [clinicaltrials_resource:ece3c3145fa7fb5960b1124b411995d6]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00454337

verification date [clinicaltrials_vocabulary:verification-date]

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00454337

http://www.w3.org/2001/XMLSchema#string

title

Efficacy and Tolerance of the ...... s With Undetectable Viral Load

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy and Tolerance of the ...... d [clinicaltrials:NCT00454337]

@en